Susobhan Sarkar

Susobhan Sarkar

Auto-generated profile, based on publicly available information

Susobhan Sarkar

Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2018 in OncoImmunology
Verified
Journal Article
Open access
RMReza Mirzaei
Reza Mirzaei
SSSusobhan Sarkar
Susobhan Sarkar
LDLauren Dzikowski
Lauren Dzikowski
KRKhalil S. Rawji
Khalil S. Rawji
LKLubaba Khan
Lubaba Khan
VYV. Wee Yong
V. Wee Yong
The dismal prognosis of glioblastoma is attributed in part to the existence of stem-like brain tumor-initiating cells (BTICs) that are highly radio- and chemo-resistant. New approaches such as therapies that reprogram compromised immune cells against BTICs are needed. Effective immunotherapies in glioblastoma, however, remain elusive unless the mechanisms of immunosuppression by the tumor are better understood. Here, we describe that while the conditioned media of activated T lymphocytes reduce the growth capacity of BTICs, this growth suppression was abrogated in live co-culture of BTICs with T cells. We present evidence that BTICs produce the extracellular matrix protein tenascin-C (TNC) to inhibit T cell activity in live co-culture. In human glioblastoma brain specimens, TNC was widely deposited in the vicinity of T cells. Mechanistically, TNC inhibited T cell proliferation through interaction with α5β1 and αvβ6 integrins on T lymphocytes associated with reduced mTOR signaling. Strikingly, TNC was exported out of BTICs associated with exosomes, and TNC-depleted exosomes suppressed T cell responses to a significantly lesser extent than control. Finally, we found that circulating exosomes from glioblastoma patients contained more TNC and T cell-suppressive activity than those from control individuals. Taken together, our study establishes a novel immunosuppressive role for TNC associated with BTIC-secreted exosomes to affect local and distal T lymphocyte immunity.

1 April 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SSSusobhan Sarkar
Susobhan Sarkar
RYRunze Yang
Runze Yang
RMReza Mirzaei
Reza Mirzaei
KRKhalil Rawji
Khalil Rawji
CPCandice Poon
Candice Poon
VYV. Wee Yong
V. Wee Yong
By rejuvenating the deficient activity of myeloid cells in glioblastoma, niacin improves the treatment of otherwise incurable brain tumors.

5 November 2021 in Science Advances
Verified
Journal Article
Open access
RMReza Mirzaei
Reza Mirzaei
AGAshley Gordon
Ashley Gordon
FZFranz J. Zemp
Franz J. Zemp
MKMehul Kumar
Mehul Kumar
SSSusobhan Sarkar
Susobhan Sarkar
VYV. Wee Yong
V. Wee Yong
PD-1 on glioblastoma cells promotes brain tumor growth, and therapeutic antibodies cannot suppress its proliferative effects.

1 June 2018 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Closed access
PDF file
CPCandice C. Poon
Candice C. Poon
RYRunze Yang
Runze Yang
TSTanveer Sheikh
Tanveer Sheikh
KLKatherine Liu
Katherine Liu
SSSusobhan Sarkar
Susobhan Sarkar
JKJohn J. Kelly
John J. Kelly
Background: CNS innate immune cells, microglia and macrophages (MMs), are the largest component of the inflammatory infiltrate in glioblastoma (GBM). They initially participate in tumor surveillance, but are subverted by GBM. Immunotherapies have proven incredibly successful in cancers such as melanoma, but not against GBM in part because GBM-associated MMs are not well understood. We hypothesized the content and inflammatory phenotype of MMs in GBM is variable between patients. We suspect MMs in IDH-wildtype and –mutant GBMs display divergent inflammatory phenotypes that helps explain the latter's better prognosis. Understanding GBM-associated MM heterogeneity will allow for better immunotherapy development and selection. Methods: MMs were isolated from untreated human IDH-wildtype and -mutant GBMs using flow cytometry and cultured for collection of conditioned media and analysis of secretory products. Automated segmentation with a high-content analysis system was used to quantitate MM content and inflammatory phenotype in frozen sections. New bioinformatics techniques allowed the comparison of MM profiles in publicly available single-cell RNA-sequencing databases with IDH-wildtype and -mutant GBMs. Results: Surprisingly marked variation in MM content exists between GBMs ranging from ~0-70%. A mixture of pro- and anti-inflammatory MMs are found in each GBM. Interestingly, IDH-mutant GBM-associated MMs were more activated than MMs in IDH-wildtype GBMs. Conclusions: Taken together, the highly variable MM content and phenotype of GBMs suggests the success of immunotherapies hinges on taking a precision medicine approach. MM-rich GBMs would benefit more from therapies that target them. MM activation in IDH-mutant GBMs may contribute to better patient prognoses.